➡️ Do you want to receive pharma updates like this one straight to your email?
📩 Subscribe to my newsletter: buff.ly/4hHF1gM

⚆ Revenue of $54.1 billion (+18% Y/Y), driven by strong performance in oncology, cardiovascular, renal & metabolism (CVRM), and rare diseases.

⚆ AZ Lilly invested $13.6 billion in R&D, making up 25% of its revenue. They also invested 35% of their revenue in SG&A.

➡️ Do you want to receive pharma updates like this one straight to your email?
📩 Subscribe to my newsletter: buff.ly/4hHF1gM

➡️ Do you want to receive pharma updates like this one straight to your email?
📩 Subscribe to my newsletter: http://buff.ly/4hHF1gM

⚆ GSK reported $39.8 billion in revenue, reflecting a 3% Y/Y growth.

⚆ Specialty medicines for HIV, respiratory, and immunology are a big part of their portfolio, generating over $11.8 billion in sales.

⚆ GSK invested $8.1 billion in R&D, making up 20% of its revenue.

➡️ Do you want to receive pharma updates like this one straight to your email?
📩 Subscribe to my newsletter: buff.ly/4hHF1gM

➡️ Do you want to receive pharma updates like this one straight to your email?
📩 Subscribe to my newsletter: buff.ly/4hHF1gM

Revenue reflects not only profitability but also a company’s strategy (e.g., investments in R&D, manufacturing, etc.) and healthcare market dynamics (e.g., oncology and immunology remain top therapeutic areas).

➡️ Do you want to receive pharma updates like this one straight to your email?
📩 Subscribe to my newsletter: buff.ly/4hHF1gM

⚆ Lilly reported $45.0 billion in revenue, reflecting a 32% Y/Y growth.

⚆ Diabetes and obesity are becoming significant contributors to Eli Lilly's portfolio - Mounjaro generated $11.5 billion, Zepbound - $4.9B.

⚆ Lilly invested $11.0 billion in R&D, making up 24% of its revenue.

➡️ Do you want to receive pharma updates like this one straight to your email?
📩 Subscribe to my newsletter: https://buff.ly/4hHF1gM

⚆ AbbVie reported USD 56.3 billion (+4% Y/Y) in net sales.

⚆ Immunology (USD 26.7B), neuroscience (USD 9.0B) and oncology (USD 6.6B) dominated their portfolio.

⚆ AbbVie invested USD 12.8B (22.7% of revenue) into research and development (R&D).

NBC News recently highlighted the case of Wedam, who underwent the treatment at Children's National Hospital in Washington, D.C.

Here is the link: https://buff.ly/3EqAeBK

#cgt #biotech #pharma #drjojo

This brings a total of 43 CGT in the US market and 20 ATMPs in the European market.

𝘞𝘩𝘢𝘵 𝘢𝘱𝘱𝘳𝘰𝘷𝘢𝘭𝘴 𝘢𝘯 𝘸𝘦 𝘦𝘹𝘱𝘦𝘤𝘵 𝘪𝘯 2025?

#genetherapy #pharma #biotech #drjojo

*These include cell therapies, gene therapies or tissue engineering products

In previous years, pharma companies would simply increase prices to offset losses. Thankfully, this strategy is no longer valid due to the Inflation Reduction Act passed under the Biden Administration.

𝘏𝘰𝘸 𝘸𝘪𝘭𝘭 𝘱𝘩𝘢𝘳𝘮𝘢 𝘤𝘰𝘮𝘱𝘦𝘯𝘴𝘢𝘵𝘦 𝘧𝘰𝘳 𝘵𝘩𝘦𝘴𝘦 𝘭𝘰𝘴𝘴𝘦𝘴?

This is not the first time we have faced a patent cliff, but this one feels different.

Firstly, more biologics will face loss of exclusivity (LoE) this time, with biosimilars adding to the pressure by offering more affordable solutions.